Inflammatory biomarkers: Impact for diabetes and diabetic vascular disease

Acta Biochimica et Biophysica Sinica

Volumn 47, Issue 12, 2015, Pages 1029-1031

  Bosevski, Marijan ^a   Stojanovska, Lily ^b   Apostolopoulos, Vasso ^b  

^a SS CYRIL AND METHODIUS UNIVERSITY OF SKOPJE   (Macedonia)

^b VICTORIA UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

DIABETES MELLITUS; DIABETIC ANGIOPATHY; HUMAN; INFLAMMATION; METABOLISM; RISK FACTOR;

BIOMARKERS; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; HUMANS; INFLAMMATION; RISK FACTORS;

EID: 84950983209     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmv109     Document Type: Article

References (35)

1. Apostolopoulos V, Borkoles E, Polman R, Stojanovska L. Physical and immunological aspects of exercise in chronic diseases. Immunotherapy 2014, 6: 1145-1157
2. Fatone C, Guescini M, Balducci S, Battistoni S, Settequattrini A, Pippi R, Stocchi L, et al. Two weekly sessions of combined aerobic and resistance exercise are sufficient to provide beneficial effects in subjectswith type 2 diabetes mellitus and metabolic syndrome. J Endocrinol Invest 2010, 33: 489-495
3. Stojanovska L, Apostolopoulos V, Polman R, Borkoles E. To exercise, or, not to exercise, during menopause and beyond. Maturitas 2014, 77: 318-323
4. Smyth S, Heron A. Diabetes and obesity: the twin epidemics. Nat Med 2006, 12: 75-80
5. Raggi P, Cooil B, Ratti C, Callister TQ, Budoff M. Progression of coronary artery calcium and occurrence of myocardial infarction in patients with and without diabetes mellitus. Hypertension 2005, 46: 238-243
6. Sander D, Schulze-Horn C, Bickel H, Gnahn H, Bartels E, Conrad B. Combined effects of hemoglobin A1c and C-reactive protein on the progression of subclinical carotid atherosclerosis: the INVADE study. Stroke 2006, 37: 351-357
7. Steiner G. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the diabetes atherosclerosis intervention study, a randomised study. Lancet 2001, 357: 905-910
8. Forst T, Wilhelm B, Pfutzner A, Fuchs W, Lehmann U, Schaper F, Weber M, et al. Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk. Diab Vasc Dis Res 2008, 5: 298-303
9. Coen PM, Flynn MG, Markofski MM, Pence BD, Hannemann RE. Adding exercise to rosuvastatin treatment: influence on C-reactive protein, monocyte toll-like receptor 4 expression, and inflammatory monocyte (CD14+CD16+) population. Metabolism 2010, 59: 1775-1783
10. Mayadas T. Apoptosis and inflammation. In Schmid-Schonbein GW, Neil Granger D (eds). Molecular Basis for Microcirculatory Disorders. Paris: Springer, 2003
11. Saremi A, Anderson RJ, Luo P, Moritz TE, Schwenke DC, Allison M, Reaven PD, et al. Association between IL-6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT). Atherosclerosis 2009, 203: 610-614
12. DeFuria J, Belkina AC, Jagannathan-Bogdan M, Snyder-Cappione J, Carr JD, Nersesova YR, Markham D, et al. B cells promote inflammation in obesity and type 2 diabetes through regulation of T cell function and an inflammatory cytokine profile. Proc Natl Acad Sci USA 2013, 110: 5133-5138
13. Zhao R, Tang D, Yi S, Li W, Wu C, Lu Y, Hou X, et al. Elevated periphera frequencies of Th22 cells: a novel potent participant in obesity and type 2 diabetes. PLoS One 2014, 9: e85770
14. Zhao RX, Li WJ, Lu YR, Qin J, Wu CL, Tian M, He TY, et al. Increased peripheral proinflammatory T helper subsets contribute to cardiovascular complications in diabetic patients. Mediators Inflamm 2014, 2014: 596967
15. Dalmas E, Venteclef N, Caer C, Poitou C, Cremer I, Aron-Wisnewsky J, Lacroix-Desmazes S, et al. T cell-derived IL-22 amplifies IL-1beta-driven inflammation in human adipose tissue: relevance to obesity and type 2 diabetes. Diabetes 2014, 63: 1966-1977
16. Fabbrini E, Cella M, McCartney SA, Fuchs A, Abumrad NA, Pietka TA, Chen Z, et al. Association between specific adipose tissue CD4+ T-cell populations and insulin resistance in obese individuals. Gastroenterol 2013, 145: 366-374
17. Magalhaes I, Pingris K, Poitou C, Bessoles S, Venteclef N, Kiaf B, Beaudoin L, et al. Mucosal-associated invariant T cell alterations in obese and type 2 diabetic patients. J Clin Invest 2015, 125: 1752-1762
18. Hayden MR, Tyagi SC. Intimal redox stress: accelerated atherosclerosis in metabolic syndrome and type 2 diabetes mellitus. Cardiovasc Diabetol 2002, 1: 3
19. Apetrei E, Ciobanu-Jurcut R. Relationship between diabetes and atherosclerosis-the role of inflammation. In Cheta D (ed). Vascular Involvment in diabetes. Freiburg: Karger, 2005
20. Isordia-Salas I, Galvan-Plata ME, Leanos-Miranda A, Aguilar-Sosa E, Anaya- Gomez F, Majluf-Cruz A, Santiago-German D. Proinflammatory and prothrombotic state in subjects with different glucose tolerance status before cardiovascular disease. J Diabetes Res 2014, 2014: 631902
21. Bruno G, Cavallo-Perin P, Bargero G, Borra M, D'Errico N, Macchia G, Pagano G. Hyperfibrinogenemia and metabolic syndrome in type 2 diabetes: a population-based study. Diabetes 2001, 17: 124-130
22. Lam TH, Liu LJ, Janus ED, Lam KS, Hedley AJ, Hong Kong Cardiovascular Risk Factor Prevalence Study Steering Committee. Fibrinogen, other cardiovascular risk factors and diabetes mellitus in Hong Kong: a community with high prevalence of type 2 diabetes mellitus and impaired glucose tolerance. Diabet Med 2000, 17: 798-806
23. Tan KC, Chow WS, Tam S, Bucala R, Betteridge J. Association between acute-phase reactants and advanced glycation end products in type 2 diabetes. Diabetes Care 2004, 27: 223-228
24. Apostolopoulos V, De Courten M, Stojanovska L. Obesity: an immunological perspective. J Immune Res 2014, 1: 3
25. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006, 444: 840-846
26. Kahn SE, Zinman B, Haffner SM, O'Neill MC, Kravitz BG, Yu D, Freed MI, et al. Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes. Diabetes 2006, 55: 2357-2364
27. Apostolopoulos V, De Courten MP, Stojanovska L, Blatch GL, Tangalakis K, De Courten B. The complex immunological and inflammatory network of adipose tissue in obesity. Mol Nutr Food Res 2015. doi: 10.1002/mnfr.201500272
28. Derosa G, Fogari E, Cicero AF, D'Angelo A, Ciccarelli L, Piccinni MN, Pricolo F, et al. Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. Hypert Res 2007, 30: 387-394
29. Artese HP, Foz AM, Rabelo Mde S, Gomes GH, Orlandi M, Suvan J, D'Aiuto F, et al. Periodontal therapy and systemic inflammation in type 2 diabetes mellitus: a meta-analysis. PLoS One 2015, 10: e0128344
30. Ebrahimi A, Nabipour I, Vahdat K, Jafari SM, Fouladvand M, Assadi M, Movahed A, et al. High sensitivity C-reactive protein is associated with the metabolic syndrome independent to viral and bacterial pathogen burden. Diabetes Res Clin Pract 2009, 84: 296-302
31. Wang X, Bao W, Liu J, Ouyang YY, Wang D, Rong S, Xiao X, et al. Inflammatory markers and risk of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care 2013, 36: 166-175
32. Hadi HA, Al Suwaidi J. Endothelial dysfunction in diabetes mellitus. Vasc Health Risk Manag 2007, 3: 853-876
33. Grossmann V, Schmitt VH, Zeller T, Panova-Noeva M, Schulz A, Laubert- Reh D, Juenger C, et al. Profile of the immune and inflammatory response in individuals with prediabetes and type 2 diabetes. Diabetes Care 2015, 38: 1356-1364
34. Coppola G, Corrado E, Muratori I, Tantillo R, Vitale G, Lo Coco L, Novo S. Increased levels of C-reactive protein and fibrinogen influence the risk of vascular events in patients with NIDDM. IntJ Cardiol 2006, 106: 16-20
35. Thorand B, Baumert J, Chambless L, Meisinger C, Kolb H, Doring A, Lowel H, et al. Elevated markers of endothelial dysfunction predict type 2 diabetes mellitus in middle-aged men and women from the general population. Arterioscler Thromb Vasc Biol 2006, 26: 398-405